Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialKeunchil Park, Luis Paz‐Ares, Vera Hirsh et al.|The Lancet Oncology|2016Cited by 1.2k
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid CancersLori J. Wirth, Maria E. Cabanillas, Eric J. Sherman et al.|New England Journal of Medicine|2020Cited by 766
Patient-Derived First Generation Xenografts of Non–Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized ChemotherapyXin Dong, Yuzhuo Wang, Jun Guan et al.|Clinical Cancer Research|2010Cited by 195